机构：[1]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China[2]PET/CT Center, Department of Radiology, Sichuan Cancer Hospital, Chengdu 610041, China四川省肿瘤医院[3]Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院
Background: While F-18-Fluoromisonidazole (F-18-FMISO) is the most frequently used positron emission tomography (PET) tracer for detecting hypoxia, it has not been studied in a metastatic triple-negative [lack expression of estrogen receptor (ER), progesterone receptor (PR) and human EGF receptor 2 (HER2)] human breast cancer cell xenografts model to our best knowledge. This study focuses on whether F-18-FMISO can detect the hypoxic status of triple-negative human breast cancer (TNBC). Methods: The TNBC cells MDA-MB-231 were successfully inoculated in right forelimb of nude mice. Nude mice models with TNBC xenografts were assessed by micro-PET imaging with F-18-FMISO, and hypoxic status of the TNBC xenografts was determined by immunohistochemistry. We also compared F-18-FDG uptake, the most commonly used PET tracer in clinical practice, with F-18-FMISO uptake to find out its correlation in MDA-MB-231 xenografts. Results: For F-18-FMISO, intestines and liver as well as bladder could be seen in micro-PET images. F-18-FDG showed physiologically high uptake in brain, heart, bladder and intestinal tracts. The quantitative radioactivity of F-18-FMISO and 18F-FDG in tumor were 2.18 +/- 0.15 and 3.84 +/- 0.54 % ID/g, respectively. The quantitative radioactivity of F-18-FMISO and F-18-FDG in muscle were 1.23 +/- 0.08 and 0.59 +/- 0.09 % ID/g, respectively. The tumor-to-muscle ratios were 1.79 +/- 0.015 and 7.11 +/- 2.84 for F-18-FMISO and F-18-FDG, respectively. Immunofluorescent images from MDA-MB-231 cryosections showed significant hypoxia. Conclusions: F-18-FMISO PET may be used for detection of hypoxia in tumor microenvironment of triple negative human breast cancer.
基金：
National Key Basic Research Program of China (2013CB933903), National Key Technology R&D Program (2012BAI23B08), National Natural Science Foundation of China (20974065, 51173117 and 50830107), Program for Changjiang Scholars, Innovative Research Team in University (PCSIRT, Grant No. IRT1272) of China and Science and Technology Foundation of Sichuan Province (2015JY0026).
第一作者机构：[1]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China[2]PET/CT Center, Department of Radiology, Sichuan Cancer Hospital, Chengdu 610041, China
通讯作者：
通讯机构：[1]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China[3]Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China[*1]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China.
推荐引用方式(GB/T 7714)：
Cheng Zhuzhong,Jiang Xiao,Yang Li,et al.Micro PET imaging of F-18-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model[J].TRANSLATIONAL CANCER RESEARCH.2016,5(3):277-284.doi:10.21037/tcr.2016.06.07.
APA：
Cheng, Zhuzhong,Jiang, Xiao,Yang, Li,Shen, Taipeng,Wang, Xiaoxiong...&Ai, Hua.(2016).Micro PET imaging of F-18-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model.TRANSLATIONAL CANCER RESEARCH,5,(3)
MLA：
Cheng, Zhuzhong,et al."Micro PET imaging of F-18-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model".TRANSLATIONAL CANCER RESEARCH 5..3(2016):277-284
